Why the study?
Does RUC-4, a novel intramuscular αIIbβ3 antagonist, effectively inhibit platelet aggregation and prevent thrombosis in preclinical models?
Does RUC-4, a novel intramuscular αIIbβ3 antagonist, effectively inhibit platelet aggregation and prevent thrombosis in preclinical models?
RUC-4 is a novel, highly soluble αIIbβ3 antagonist that rapidly and reversibly inhibits platelet aggregation via intramuscular injection in preclinical models, showing promise for prehospital myocardial infarction treatment.
Answers are grounded in this paper and cite their sources.
Supports IM RUC-4 development for rapid platelet inhibition; leaves open human translation and clinical utility.
OBJECTIVE: Treatment of myocardial infarction within the first 1 to 2 hours with a thrombolytic agent, percutaneous coronary intervention, or an αIIbβ3 antagonist decreases mortality and the later development of heart failure. We previously reported on a novel small molecule αIIbβ3 antagonist, RUC-2, that has a unique mechanism of action. We have now developed a more potent and more soluble congener of RUC-2, RUC-4, designed to be easily administered intramuscularly by autoinjector to facilitate its use in the prehospital setting. Here, we report the properties of RUC-4 and the antiplatelet and antithrombotic effects of RUC-2 and RUC-4 in animal models. APPROACH AND RESULTS: RUC-4 was ≈ 20% more potent than RUC-2 in inhibiting human ADP-induced platelet aggregation and much more soluble in aqueous solutions (60-80 mg/mL). It shared RUC-2's specificity for αIIbβ3 versus αVβ3, did not prime the receptor to bind fibrinogen, or induce changes in β3 identified by a conformation-specific monoclonal antibody. Both RUC-2 and RUC-4 prevented FeCl3-induced thrombotic occlusion of the carotid artery in mice and decreased microvascular thrombi in response to laser injury produced by human platelets infused into transgenic mice containing a mutated von Willebrand factor that reacts with human but not mouse platelets. Intramuscular injection of RUC-4 in nonhuman primates at 1.9 and 3.85 mg/kg led to complete inhibition of platelet aggregation within 15 minutes, with dose-dependent return of platelet aggregation after 4.5 to 24 hours. CONCLUSIONS: RUC-4 has favorable biochemical, pharmacokinetic, pharmacodynamic, antithrombotic, and solubility properties as a prehospital therapy of myocardial infarction, but the possibility of increased bleeding with therapeutic doses remains to be evaluated.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: